Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024
SAN RAFAEL, Calif., April 22, 2024 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader […]
WTW appoints Lombardo Chair of the Real Estate, Hospitality, and Leisure (REHL) Division, CRB NA
NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) — WTW (NASDAQ: WTW), a leading global advisory, broking, and solutions company, today […]
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
New York, NY, April 22, 2024 (GLOBE NEWSWIRE) — Fresh2 Group Ltd. (NASDAQ: FRES) (“Fresh2” or the “Company”), a B2B […]
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
Boca Raton, Florida, April 22, 2024 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused […]
DLH to Announce Fiscal 2024 Second Quarter Financial Results
ATLANTA, April 22, 2024 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and […]
VERB’s MARKET.live Adds Another 100 Retail Brands to Its Livestream Social Shopping Platform
LOS ALAMITOS, Calif. and LAS VEGAS, April 22, 2024 (GLOBE NEWSWIRE) — Verb Technology Company, Inc. (Nasdaq: VERB) (“VERB” or […]
Southern States Bancshares, Inc. Announces First Quarter 2024 Financial Results
First Quarter 2024 Performance and Operational Highlights Net income of $8.1 million, or $0.90 per diluted share Core net income(1)of […]
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of […]
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial […]
Aterian Announces Improved First Quarter 2024 Net Revenue and Adjusted EBITDA Ranges
First Quarter Net Revenue Range Improved to $20.0 Million to $21.0 Million First Quarter Adjusted EBITDA Loss Range Improved to […]
